GlaxoSmithKlein pledges patent pool for neglected diseases
Category: Business & Economics | Health, Science & EducationPublished on Feb 16, 2009
Some time ago, I reported that Novartis had adopted a wikinomics approach to its diabetes research. After investing millions of dollars trying to unlock the genetic basis of type 2 diabetes, the company released all of its raw data on the Internet, for free. Hardly typical behavior for a pharmaceutical company. After all, pinpointing their precise genetic origins of diabetes could unlock a treasure trove of new medicines and result in a major windfall for [...]
1 Comments

Read More